Dec 13 (Reuters) - The European Medicines Agency said on

Friday Eli Lilly's weight-loss drug does not need a

separate approval for the treatment of a sleep disorder called

obstructive sleep apnea (OSA).

The health agency considered that the use of Mounjaro is

already covered by the approved indication for weight management

and that a separate indication for the treatment of moderate to

severe OSA in adults with obesity is not needed.